Loading
Getting a cell line, mouse model or antibody from another lab can take six months of paperwork. Funders would require a standard agreement that goes through automatically unless someone objects within thirty days.
Funders and journals require that materials generated with their support are shared under the Uniform Biological Material Transfer Agreement or an equivalent open template (for example the OpenMTA for tool reagents), with institutions committing to a thirty-day default-approve process for non-commercial requests and to deposit the most requested reagents in repositories (Addgene, ATCC, JAX, EurOPDX). Material access delays are a documented cause of failed replications and slow translation; the fix is procedural, not scientific, and costs almost nothing.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.
Shares Promote academics for trials completed, data shared and findings replicated, Secrecy and intellectual property block collaboration, Preclinical results do not reproduce.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids.
Shares Patient-derived xenografts, Preclinical results do not reproduce, Patient-derived organoids.
Shares Cancer Models (PDCM Finder) & HCMI, Preclinical results do not reproduce.